Take Solutions Ltd Q2FY26 – The Clinical Trials Company That Ended Up On Its Own Life Support
1. At a Glance
Take Solutions Ltd once promised to be India’s digital healthcare disruptor — now it’s a case study in how a once-global clinical research empire can implode faster than a biotech trial gone wrong. The stock, now trading at ₹23.7, is up 195% in 6 months — but before you clap, remember it’s a rebound from ₹6.5 levels.
With a market cap of ₹351 crore, a laughable P/E of 87.9, and book value of ₹1.73, the company’s fundamentals are thinner than the consent forms in a Phase-I trial. The Singapore promoter dumped nearly 48% of their stake this quarter, leaving promoter holding at just 5.19%. The statutory auditor quit mid-year citing “fee disagreement.” The board, in Q2FY26, admitted to ₹69.7 crore losses, “going concern doubts,” and pending tax litigations worth ₹72 crore.
Once a life sciences darling, now an operating ghost town with zero sales for the last five quarters. Only “other income” keeps the ECG from going flat.
The only question left: is this revival real or just the final flicker before the ventilator plug is pulled?
2. Introduction
At the turn of the millennium, Take Solutions was the biotech IT dream — the software kid that wanted to heal the world. Its founder, armed with domain knowledge and global ambitions, built a clinical research network spanning India, Singapore, the US, and Europe.
Then came the pandemic, the debt, and the domino effect. By FY23, the company was forced to sell its crown jewel — Take Solutions Global Holdings Pte Ltd (Singapore) — to lender HIG Capital after a loan default. The sale left behind a ₹38 crore breadcrumb, of which ₹30 crore was actually received.
Since then, the company has dissolved subsidiaries (Acunova Life Science, Navitas Life Sciences Thailand), shut down international units, and is now surviving through a lone Indian entity, Ecron Acunova, which still runs a few bio-equivalence trials.
Imagine a hospital with a single functioning ward — that’s Take Solutions in FY26.
3. Business Model – WTF Do They Even Do?
In theory, Take Solutions provides end-to-end clinical research, regulatory filing, and pharmacovigilance services to global pharma companies. In practice, they used to do that — before most of those businesses were sold or dissolved.
Now the group’s revenue (whatever little there is) comes from:
Bioequivalence & Bioavailability Studies – via Ecron Acunova, focusing on early-phase trials and healthy volunteer studies.
Consulting Services – digital transformation for healthcare, AI-based diagnostics, billing insights, and cloud integration (though recent reports suggest no active contracts).
Interest & Other Income – because at this point, even bank interest is more reliable than client renewals.
They’re expanding Ecron’s Manipal facility to 150 beds for clinical trials, investing ₹12 crore. A decent plan — but when your topline is ₹0 and your auditors resign, the only trial left is in patience.
